Opinion|Videos|August 7, 2024

First-Line Immune Checkpoint Inhibitors for Poor Risk Metastatic RCC

Key opinion leaders in renal cell carcinoma provide a comprehensive overview of first-line immune checkpoint inhibitor combination regimens for patients with intermediate-to-poor risk metastatic renal cell carcinoma.


Latest CME